S&S Business Summary

S&S Healthcare Holding Ltd. (4198.TWO) is a Taiwan-based investment holding company specializing in the global medical imaging sector, primarily generating revenue through the research, development, and sale of high-end diagnostic equipment. Its business model is centered on the manufacturing of digital radiography (DR) systems, bone densitometry, and body composition assessment products, complemented by recurring revenue from installation, maintenance, and technical upgrade services for 1.5 Tesla MRI devices. The company operates across Taiwan, the United States, and Europe, utilizing a dual-brand strategy to capture both high-end clinical demand and broader diagnostic markets. Key competitors include Puriblood Medical, Ttbio, MicroBase Technology, and AmCad BioMed; S&S distinguishes itself as a specialized provider of Swiss-engineered digital X-ray solutions with a robust aftermarket service infrastructure that supports long-term client retention in the medical imaging space. The company is led by Chairman Pei-Lin Lee and COO/Director Tien-Ying Lee, both of whom have held their leadership positions since 2018 and oversaw the firm’s 2020 transition from its former identity as Swissray Global Healthcare Holding Ltd. The board of directors features a mix of industry veterans and independent oversight, including Director Guo-Dong Lin, Director Yung-Chih Ting, and Independent Directors Mu-Chi Huang and Chia-Cheng Chang. Founded in 1988 and headquartered in Taipei, S&S maintains a deep pedigree in precision medical technology derived from its original Swissray roots. Following its 2014 listing on the TPEx, the leadership has focused on geographic expansion into Southeast Asia and the modernization of its product portfolio to address evolving global diagnostic trends while maintaining a lean operational structure.